Aleksander Maciąg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aleksander Maciąg has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
- Hanna Szwed
On behalf of the STICH-Family: cardiologists and cardiac surgeons forming the STICH trial team in Poland
3 shared publications - Mariusz Pytkowski
Arrhythmia Centre National Institute of Cardiology Warsaw Poland
3 shared publications - Michal Miroslaw Farkowski
Department of Cardiology, Ministry of Interior and Administration National Medical Institute , Wołoska 137, Warsaw 02-507
3 shared publications - Ilona Kowalik
Department of Coronary Artery Disease and Cardiac Rehabilitation, National Institute of Cardiology, 04-628 Warsaw, Poland
2 shared publications - Maciej Sterliński
1st Department of Arrhythmia, National Institute of Cardiology, 04-628 Warsaw, Poland
2 shared publications Mariusz Pytkowski
2nd Department of Arrhythmia, National Institute of Cardiology, Warszawa, Poland
2 shared publications
Latest Publications
- Open Access
- 15 May 2024
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 82 (6) , 670-671
Peak frequency analysis and differentiation of near-field from far-field electrograms of the ventricular tachycardia circuit leads to successful ablation of the arrhythmia
- 15 May 2024
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 82 (6) , 670-671
Open AccessPeak frequency analysis and differentiation of near-field from far-field electrograms of the ventricular tachycardia circuit leads to successful ablation of the arrhythmia
- 25 September 2020
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 78 (9) , 928-929
Identification of the ventricular tachycardia circuit using the Advisor HD Grid multielectrode mapping catheter
- 25 September 2020
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 78 (9) , 928-929
Identification of the ventricular tachycardia circuit using the Advisor HD Grid multielectrode mapping catheter
- 31 January 2017
- Published by Fundacja Heart Beat in Heart Beat Journal
- Vol. 1, 61-62
Incessant form of a benign arrhythmia in a patient with a DDD pacemaker.
Authors present the case of an 83-year old male with the dual chamber pacemaker implanted due to a tachycardia-bradycardia syndrome and with an incessant form of atrioventricular nodal re-entrant tachycardia (AVNRT). Intracardiac electrogram with the retrograde atrial depolarization helps to...
- 31 January 2017
- Published by Fundacja Heart Beat in Heart Beat Journal
- Vol. 1, 61-62
Incessant form of a benign arrhythmia in a patient with a DDD pacemaker.
Authors present the case of an 83-year old male with the dual chamber pacemaker implanted due to a tachycardia-bradycardia syndrome and with an incessant form of atrioventricular nodal re-entrant tachycardia (AVNRT). Intracardiac electrogram with the retrograde atrial depolarization helps to...
- 29 December 2016
- Published by Fundacja Heart Beat in Heart Beat Journal
- Vol. 1, 15-17
Bizarre Intracardiac Electrogram as an ICD Lead Damage Early Manifestation
Implantable cardioverter-defibrillator (ICD) therapy is associated with an increasing number of ICD lead-related complications. We present a case of 52-year-old female treated with ICD for the post-infarction primary prophylaxis in whom inappropriate shocks were caused by lead damage manifested...
- 29 December 2016
- Published by Fundacja Heart Beat in Heart Beat Journal
- Vol. 1, 15-17
Bizarre Intracardiac Electrogram as an ICD Lead Damage Early Manifestation
Implantable cardioverter-defibrillator (ICD) therapy is associated with an increasing number of ICD lead-related complications. We present a case of 52-year-old female treated with ICD for the post-infarction primary prophylaxis in whom inappropriate shocks were caused by lead damage manifested...
- Open Access
- 4 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Comparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)
- 4 October 2014
- Published by Springer Nature in Trials
- Vol. 15 (1) , 1-9
Open AccessComparison of the rhythm control treatment strategy versus the rate control strategy in patients with permanent or long-standing persistent atrial fibrillation and heart failure treated with cardiac resynchronization therapy - a pilot study of Cardiac Resynchronization in Atrial Fibrillation Trial (Pilot-CRAfT): study protocol for a randomized controlled trial
The only subgroups of patients with heart failure and atrial fibrillation in which the efficacy of cardiac resynchronization therapy has been scientifically proven are patients with indications for right ventricular pacing and patients after atrioventricular junction ablation. However it is unlikely that atrioventricular junction ablation would be a standard procedure in the majority of the heart failure patients with cardiac resynchronization therapy and concomitant atrial fibrillation due to the irreversible character of the procedure and a spontaneous sinus rhythm resumption that occurs in about 10% of these patients. Pilot-CRAfT is the first randomized controlled trial evaluating the efficacy of a rhythm control strategy in atrial fibrillation patients with cardiac resynchronization therapy devices. The aim of this prospective, single center randomized controlled pilot study is to answer the question whether the patients with cardiac resynchronization therapy and permanent atrial fibrillation would benefit from a strategy to restore and maintain sinus rhythm (that is ‘rhythm control’ strategy) in comparison to rate control strategy. The study population consists of 60 patients with heart failure and concomitant long-standing persistent or permanent atrial fibrillation who underwent a cardiac resynchronization therapy device implantation at least 3 months before qualification. Study participants are randomly assigned to the rhythm control strategy (including electrical cardioversion and pharmacotherapy) or to the rate control group whose goal is to control ventricular rate. The follow-up time is 12 months. The primary endpoint is the ratio of effectively captured biventricular beats. The secondary endpoints include peak oxygen consumption, six-minute walk test distance, heart failure symptom escalation, reverse remodelling of the heart on echo and quality of life. NCT01850277 registered on 22 April 2013 (ClinicalTrails.gov)
- Open Access
- 11 September 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 162
Clinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)
Rapid conversion of atrial fibrillation (AF) to sinus rhythm may be achieved by the administration of class IA, IC and III antiarrhythmic drugs or vernakalant hydrochloride. However, that treatment may be related to potential pro-arrhythmia, lack of efficacy or the exceptionally high cost of a compound used. Antazoline is a first generation antihistaminic agent with chinidin-like properties. When administered intravenously, antazoline exerts a strong antiarrhythmic effect on supraventricular arrhythmia, especially on AF, facilitating rapid conversion to sinus rhythm. Despite a relative lack of published data antazoline has been marketed in Poland and widely used in cardiology wards and emergency rooms for many years due to its efficacy, safety and rapid onset of action within minutes of administration.
- 11 September 2012
- Published by Springer Nature in Trials
- Vol. 13 (1) , 162
Open AccessClinical efficacy of antazoline in rapid cardioversion of paroxysmal atrial fibrillation -- a protocol of a single center, randomized, double-blind, placebo-controlled study (the AnPAF Study)
Rapid conversion of atrial fibrillation (AF) to sinus rhythm may be achieved by the administration of class IA, IC and III antiarrhythmic drugs or vernakalant hydrochloride. However, that treatment may be related to potential pro-arrhythmia, lack of efficacy or the exceptionally high cost of a compound used. Antazoline is a first generation antihistaminic agent with chinidin-like properties. When administered intravenously, antazoline exerts a strong antiarrhythmic effect on supraventricular arrhythmia, especially on AF, facilitating rapid conversion to sinus rhythm. Despite a relative lack of published data antazoline has been marketed in Poland and widely used in cardiology wards and emergency rooms for many years due to its efficacy, safety and rapid onset of action within minutes of administration.